Fogarty International Plans February Hybrid Meeting
Published Date: 10/1/2025
Notice
Summary
The Fogarty International Center is holding a hybrid meeting on February 9-10, 2026, where part of it will be closed to review grant applications, and the rest will be open to the public to discuss current and future projects. This affects researchers applying for grants and anyone interested in global health updates. No registration is needed to join the open session, and special accommodations are available for attendees.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 0 costs, 1 mixed.
Grant Review Held in Closed Session
The Fogarty International Center Advisory Board will hold a closed meeting on February 9, 2026 from 3:00 p.m. to 5:00 p.m. to review and evaluate the second level of grant applications. The session is closed under 5 U.S.C. 552b(c)(4) and 552b(c)(6) because discussions may disclose confidential trade secrets, patentable material, or personal information.
Open Hybrid Session Accessible Without Registration
The Fogarty International Center will hold an open in-person and virtual meeting on February 10, 2026 from 9:00 a.m. to 12:30 p.m. for updates and discussion of current and planned activities. The open session can be accessed via the Fogarty website (https://www.fic.nih.gov/About/Advisory/Pages/default.aspx), does not require registration, offers special accommodations (e.g., sign language), and in-person attendees must follow NIH security procedures including showing one form of ID and vehicle inspection.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16683, Proposed Collection; 60-Day Comment Request; Data Use Certification for the NIH National Institute on Drug Abuse Data Share Site
The purpose of this notice is to inform the public of the information collection requirement for the NIDA Data Share, the data use terms and conditions, and to request a progress report statement at the time of renewal. In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-16544, Government-Owned Inventions; Availability for Licensing
The inventions listed below are owned by an agency of the U.S. Government and are available for licensing to achieve expeditious commercialization of results of federally-funded research for the benefit of the public health.
2026-16440, NIH Owned Invention Available for License: Soluble Tissue Factor, a Novel Target, and Antibodies, for Diagnosis, Prevention and Treatment of Thrombosis and Related Conditions
Scientists at the National Cancer Institute (NCI) have discovered a novel therapeutic, diagnostic and prognostic target for thrombosis: Soluble Tissue Factor (sTF). NCI has generated first-in- class antibodies and platform selectively neutralizing pathological coagulation while preserving normal hemostasis. This platform technology can be used to prevent, diagnose and treat pathological thrombosis caused by a variety of clinical conditions-including cancer, sepsis, infectious diseases (e.g., COVID), autoimmune disorders, trauma, heart conditions and inflammatory conditions. It offers a much more sensitive and specific test of thrombosis than the current D-dimer test. It may be applicable to any clinical condition which induces necroptosis, pyroptosis and NETtosis, such as cancer, neurodegenerative disease, ischemia-reperfusion and acute injuries, traumatic injuries, bacterial and viral infections, cardiovascular conditions, and atherosclerosis, inflammatory, autoimmune conditions, and others.
2026-16071, Proposed Collection; 60-Day Comment Request: The Impact of Clinical Research Training and Medical Education at the Clinical Center on Physician Careers in Academia and Clinical Research (Clinical Center)
In compliance with the requirement of the Paperwork Reduction Act of 1995, for opportunity for public comment on proposed data collection projects, the Clinical Center, the National Institutes of Health (NIH) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-15565, Proposed Collection; 60-Day Comment Request, Data Use Certification for the NIH Brain Development Cohorts (NBDC) Data Hub, (National Institute on Drug Abuse)
In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval. The purpose of this revision is to update instructions for the Research Data Use Statement and the Progress Report, and to add new instructions for attesting to National Institute of Standards & Technology (NIST) security compliance, and for a Project Close-out at the time of project completion. Burden levels remain unchanged.
2026-14964, Center for Scientific Review; Notice of Closed Meeting
The Center for Scientific Review is holding a closed virtual meeting on August 19, 2026, to review neuroscience career development grant applications. This meeting is private to protect sensitive info like trade secrets and personal details. Researchers applying for these grants should note the date, as funding decisions could impact their projects and careers.
Previous / Next Documents
Previous: 2025-19109, Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding several closed virtual meetings in November 2025 to review and evaluate grant applications. These meetings protect private info and trade secrets, affecting researchers and small businesses seeking funding. No changes to timing or money are announced, but the reviews are key to deciding who gets research grants.
Next: 2025-19111, Deregistration Under Section 8(f) of the Investment Company Act of 1940
A closed-end investment company has officially stopped being an investment company after moving its assets to MidCap Financial Investment Corporation. On July 22, 2024, it gave its final payout to shareholders, and the costs of over $9 million were covered by the new fund’s adviser. This change means the company is no longer regulated as an investment company, making things simpler for everyone involved.